Product Description
GSK-2256294 is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH. (Sourced from: https://drugs.ncats.io/substance/L33EX3XR0T)
Mechanisms of Action: EPHX Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glucose Metabolism Disorders|Prediabetes|Subarachnoid Hemorrhage|Intracranial Aneurysm|Obesity|Vasospasm, Intracranial|Brain Infarction|Ischemic Stroke|Cerebral Hemorrhage
Phase 1: Hypoxia|Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02262689 |
NCT02262689 | P1 |
Completed |
Hypoxia|Chronic Obstructive Pulmonary Disease |
2015-04-24 |
2019-03-20 |
Treatments |
|
NCT02006537 |
NCT02006537 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2014-05-27 |
2019-03-20 |
Treatments |
|
NCT01762774 |
NCT01762774 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2014-05-01 |
2019-03-19 |
Treatments |
|
NCT03486223 |
5R01DK117875 | P2 |
Completed |
Obesity|Prediabetes|Glucose Metabolism Disorders |
2021-11-18 |
2023-03-24 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT03318783 |
SUSHI | P2 |
Completed |
Ischemic Stroke|Cerebral Hemorrhage|Subarachnoid Hemorrhage|Vasospasm, Intracranial|Intracranial Aneurysm|Brain Infarction |
2019-04-03 |
21% |
2021-01-25 |
Primary Endpoints|Treatments |